Skip to main content

Advertisement

ADVERTISEMENT

Insights

Headshot of Brian Mustanski, Northwestern University
Interview
04/14/2022
Brian Mustanski, PhD, professor of medical social sciences, Northwestern University, shares factors influencing whether patients reinitiate preexposure prophylaxis for HIV after discontinuation.
Brian Mustanski, PhD, professor of medical social sciences, Northwestern University, shares factors influencing whether patients reinitiate preexposure prophylaxis for HIV after discontinuation.
Brian Mustanski, PhD, professor...
04/14/2022
First Report Managed Care
Chris Beyrer
Podcasts
06/30/2021
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, breaks down current rates of HIV across the United States as well as the challenges linked with controlling this...
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, breaks down current rates of HIV across the United States as well as the challenges linked with controlling this...
Chris Beyrer, MD, infectious...
06/30/2021
First Report Managed Care
Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
Podcasts
01/25/2021
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to...
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to...
Ed Pezalla, MD, CEO,...
01/25/2021
First Report Managed Care

Advertisement

Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection
Videos
09/23/2020
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class...
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class...
Max Lataillade, DO, head of...
09/23/2020
First Report Managed Care

Advertisement